The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Drug repositioning for Alzheimer's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Self-citationKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Self-citationLithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00011 · Cited by 1,409
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139
Self-citationThe age-dependent relation of blood pressure to cognitive function and dementia
Qiu, C., Winblad, B., & Fratiglioni, L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70141-1 · Cited by 1,138
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012244 · Cited by 813
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639
World Alzheimer Report 2010: The global economic impact of dementia
Wimo, A. B., & Prince, M. J. (2010) · Cited by 559
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey II, W. H., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13309 · Cited by 521
Insulin and the insulin receptor in experimental models of learning and memory
Zhao, W.-Q., Chen, H., Quon, M. J., & Alkon, D. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.045 · Cited by 502
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
Wozniak, M., Mee, A., & Itzhaki, R. (2009) · The Journal of Pathology · doi:10.1002/path.2449 · Cited by 464
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
Hoyer, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.049 · Cited by 434
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Hsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101524 · Cited by 372
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Gorelick, P. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05726.x · Cited by 361
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S., Rosendorff, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31547 · Cited by 335
The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function
Posner, H. B., Tang, M.-X., Luchsinger, J., Lantigua, R., Stern, Y., & Mayeux, R. (2002) · Neurology · doi:10.1212/wnl.58.8.1175 · Cited by 329
Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study
Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4f6 · Cited by 328
McGuinness, B., Todd, S., Passmore, P., & Bullock, R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub3 · Cited by 315
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 299
Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 295
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 290
Nebes, R. D., Pollock, B. G., Houck, P. R., Butters, M. A., Mulsant, B. H., Zmuda, M. D., & Reynolds, C. F. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00085-7 · Cited by 275
Ding, Y., Qiao, A., Wang, Z., Goodwin, J. S., Lee, E.-S., Block, M. L., Allsbrook, M., McDonald, M. P., & Fan, G.-H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3153-08.2008 · Cited by 269
Alzheimer-Like Changes in Rat Models of Spontaneous Diabetes
Li, Z.-G., Zhang, W., & Sima, A. A. F. (2007) · Diabetes · doi:10.2337/db07-0171 · Cited by 265
Carro, E., & Torres-Aleman, I. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.050 · Cited by 262
Anti‐amyloidogenic activity of tetracyclines: studies in vitro
Forloni, G., Colombo, L., Girola, L., Tagliavini, F., & Salmona, M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02380-2 · Cited by 242
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52109.x · Cited by 241
Brain renin-angiotensin—A new look at an old system
Wright, J. W., & Harding, J. W. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.07.001 · Cited by 233
Nimodipine for primary degenerative, mixed and vascular dementia
Birks, J., & López-Arrieta, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000147 · Cited by 230
Amantadine: The journey from fighting flu to treating Parkinson disease
Hubsher, G., Haider, M., & Okun, M. S. (2012) · Neurology · doi:10.1212/wnl.0b013e31824e8f0d · Cited by 227
Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin
Tippmann, F., Hundt, J., Schneider, A., Endres, K., & Fahrenholz, F. (2009) · The FASEB Journal · doi:10.1096/fj.08-121392 · Cited by 224
Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
Seabrook, T. J., Jiang, L., Maier, M., & Lemere, C. A. (2006) · Glia · doi:10.1002/glia.20338 · Cited by 223
Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70250-7 · Cited by 216
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212
Self-citationHamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
SKOOG, I., LITHELL, H., HANSSON, L., ELMFELDT, D., HOFMAN, A., OLOFSSON, B., TRENKWALDER, P., & ZANCHETTI, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.02.013 · Cited by 199
Fan, R., Xu, F., Previti, M. L., Davis, J., Grande, A. M., Robinson, J. K., & Van Nostrand, W. E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4371-06.2007 · Cited by 196
Stockhorst, U., de Fries, D., Steingrueber, H.-J., & Scherbaum, W. A. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.07.022 · Cited by 192
Corcoran, J. P. T., So, P. L., & Maden, M. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03563.x · Cited by 190
Self-citationEvidence for defective retinoid transport and function in late onset Alzheimer's disease
Goodman, A. B., & Pardee, A. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437937100 · Cited by 184
Chronic divalproex sodium use and brain atrophy in Alzheimer disease
Fleisher, A. S., Truran, D., Mai, J. T., Langbaum, J. B. S., Aisen, P. S., Cummings, J. L., Jack, C. R., Weiner, M. W., Thomas, R. G., Schneider, L. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a16c · Cited by 177
A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results
(2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181342f32 · Cited by 174
Angiotensins in Alzheimer's disease – friend or foe?
Kehoe, P. G., Miners, S., & Love, S. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.07.006 · Cited by 165
Self-citationA feasibility and tolerability study of lithium in Alzheimer's disease
Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 163
Scholey, A. B., Tildesley, N. T. J., Ballard, C. G., Wesnes, K. A., Tasker, A., Perry, E. K., & Kennedy, D. O. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1101-3 · Cited by 162
Self-citationTakeda, S., Sato, N., Takeuchi, D., Kurinami, H., Shinohara, M., Niisato, K., Kano, M., Ogihara, T., Rakugi, H., & Morishita, R. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.138586 · Cited by 161
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160
Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease
Danielyan, L., Klein, R., Hanson, L. R., Buadze, M., Schwab, M., Gleiter, C. H., & Frey, W. H. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0944 · Cited by 158
Anekonda, T. S., Quinn, J. F., Harris, C., Frahler, K., Wadsworth, T. L., & Woltjer, R. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.020 · Cited by 155
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Insulin-like growth factor-I, cognition and brain aging
van Dam, P. S., & Aleman, A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.047 · Cited by 149
Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells
Li, N., Liu, B., Dluzen, D. E., & Jin, Y. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.12.015 · Cited by 147
Herpes Simplex Virus Type 1 in Alzheimer's Disease: The Enemy Within
Itzhaki, R. F., & Wozniak, M. A. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13405 · Cited by 143
Telmisartan prevented cognitive decline partly due to PPAR-γ activation
Mogi, M., Li, J., Tsukuda, K., Iwanami, J., Min, L., Sakata, A., Fujita, T., Iwai, M., & Horiuchi, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.032 · Cited by 134
Ryu, J. K., Franciosi, S., Sattayaprasert, P., Kim, S. U., & McLarnon, J. G. (2004) · Glia · doi:10.1002/glia.20051 · Cited by 133
Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124
All-transretinoic acid as a novel therapeutic strategy for Alzheimer’s disease
Lee, H. P., Casadesús, G., Zhu, X., Lee, H., Perry, G. L., Smith, M. A., Gustaw‐Rothenberg, K., & Lerner, A. J. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.86 · Cited by 124
Hemming, M. L., Selkoe, D. J., & Farris, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.004 · Cited by 119
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
Čulman, J., Blume, A., Gohlke, P., & Unger, T. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001442 · Cited by 114
Neuroprotection in Huntington??s disease: a 2-year study on minocycline
Bonelli, R. M., dl, A. K. H., Hofmann, P., & Kapfhammer, H. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00004 · Cited by 111
Minocycline in Huntington's disease: A pilot study
Thomas, M., Ashizawa, T., & Jankovic, J. J. (2004) · Movement Disorders · doi:10.1002/mds.20018 · Cited by 111
A futility study of minocycline in Huntington's disease
Cudkowicz, M., & The Huntington Study Group DOMINO Investigators (2010) · Movement Disorders · doi:10.1002/mds.23236 · Cited by 107
Cohen, A. C., Tong, M., Wands, J. R., & de la Monte, S. M. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00450.x · Cited by 107
Parachikova, A. I., Vasilevko, V., Cribbs, D. H., LaFerla, F. M., & Green, K. N. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100204 · Cited by 104
Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99
Cannabinoids for the treatment of dementia
Krishnan, S., Cairns, R., & Howard, R. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007204.pub2 · Cited by 95
Li, L., Zhang, Z., Hölscher, C., Gao, C., Jiang, Y., & Liu, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.005 · Cited by 94
Towards Retinoid Therapy for Alzheimers Disease
Shudo, K., Fukasawa, H., Nakagomi, M., & Yamagata, N. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486581 · Cited by 91
Minocycline for Huntington’s disease: An open label study
Bonelli, R. M., Heuberger, C., & Reisecker, F. (2003) · Neurology · doi:10.1212/01.wnl.0000049936.85487.7a · Cited by 87
Dimebon (Latrepirdine) Enhances Mitochondrial Function and Protects Neuronal Cells from Death
Zhang, S., Hedskog, L., Petersen, C. H., Winblad, B. G., & Ankarcrona, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100174 · Cited by 86
Hölscher, C. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.3.181 · Cited by 85
Identification of Antihypertensive Drugs Which Inhibit Amyloid-β Protein Oligomerization
Zhao, W., Wang, J., Ho, L., Ono, K., Teplow, D. B., & Pasinetti, G. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0925 · Cited by 78
Jarvis, C. I., Goncalves, M. B. C. V., Clarke, E. E., Dogruel, M., Kalindjian, S. B., Thomas, S. A., Maden, M., & Corcoran, J. P. T. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07426.x · Cited by 78
Self-citationThe Role of GLP-1 in Neuronal Activity and Neurodegeneration
Hölscher, C. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00013-8 · Cited by 74
Kehoe, P., & Passmore, P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111376 · Cited by 73
Self-citationHusson, M., Enderlin, V., Delacourte, A., Ghenimi, N., Alfos, S., Pallet, V., & Higueret, P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.008 · Cited by 70
Noble, W. J., Garwood, C. J., & Hanger, D. P. (2009) · Prion · doi:10.4161/pri.3.2.8820 · Cited by 70
Cai, Z., Zhao, Y., Yao, S., & Zhao, B. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70504-7 · Cited by 65
García-Alloza, M., Prada, C. M., Lattarulo, C. R., Fine, S., Borrelli, L. A., Betensky, R. A., Greenberg, S. M., Frosch, M. P., & Bacskai, B. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06096.x · Cited by 65
Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 64
EFFECTS OF NIMODIPINE ON CEREBRAL BLOOD FLOW AND NEUROPSYCHOLOGICAL OUTCOME AFTER CARDIAC SURGERY
Forsman, M., Olsnes, B. T., Semb, G., & Steen, P. A. (1990) · British Journal of Anaesthesia · doi:10.1093/bja/65.4.514 · Cited by 63
Nimodipine in the Treatment of Probable Alzheimerʼs Disease
Morich, F., Bieber, F., Lewis, J. M., Kaiser, L., Cutler, N. R., Escobar, J. I., Willmer, J., Petersen, R. C., & Reisberg, . (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199611040-00001 · Cited by 61
Malm, T., Magga, J. M., Kuh, G. F., Vatanen, T., Koistinaho, M., & Koıstınaho, J. (2008) · Glia · doi:10.1002/glia.20726 · Cited by 56
Cuello, A. C., Ferretti, M. T., León, W., Iulita, M. F., Melis, T., Ducatenzeiler, A., Bruno, M. A., & Canneva, F. (2010) · Neurodegenerative Diseases · doi:10.1159/000285514 · Cited by 54
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
D’Onofrio, G., Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Paroni, G., Cascavilla, L., Seripa, D., & Pilotto, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.645534 · Cited by 53
So, P.-L., Yip, P. K., Bunting, S. C. J., Wong, L., Mazarakis, N. D., Hall, S., McMahon, S. B., Maden, M., & Corcoran, J. P. T. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.06.027 · Cited by 51
Self-citationCopenhaver, P. F., Anekonda, T. S., Musashe, D. T., Robinson, K. M., Ramaker, J. M., Swanson, T. L., Wadsworth, T. L., Kretzschmar, D., Woltjer, R. L., & Quinn, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006841 · Cited by 44
Kennelly, S., Abdullah, L. I., Kenny, R. A., Mathura, V. S., Luis, C. A., Mouzon, B., Crawford, F., MULLAN, M. J., & LAWLOR, B. A. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2735 · Cited by 42
Ferrington, L., Miners, J. S., Palmer, L. E., Bond, S. M., Povey, J. E., Kelly, P. A., Love, S., Horsburgh, K. J., & Kehoe, P. G. (2011) · PubMed Central · Cited by 41
Self-citationMelino, G., Draoui, M., Bernardini, S., Bellincampi, L., Reichert, U., & Cohen, P. (1996) · PubMed · Cited by 41
Kawahara, K., Nishi, K., Suenobu, M., Ohtsuka, H., Maeda, A., Nagatomo, K., Kuniyasu, A., Staufenbiel, M., Nakagomi, M., Shudo, K., et al. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1307 · Cited by 39
Goncalves, M. B. C. V., Agudo‐Barriuso, M., Connor, S., McMahon, S. B., Minger, S. L., Maden, M., & Corcoran, J. P. T. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.11.018 · Cited by 39
Self-citationKennelly, S., Abdullah, L. I., Paris, D., Parish, J., Mathura, V. S., MULLAN, M. J., Crawford, F., LAWLOR, B. A., & Kenny, R. A. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2638 · Cited by 39
Hanyu, H., Hirao, K., Shimizu, S., Iwamoto, T., Koizumi, K., & Abe, K. (2007) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32804c58aa · Cited by 39
Chen, Y., Chen, H., Lan, J.-L., & Chen, D. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.01.017 · Cited by 31
Iwasaki, K., Egashira, N., Takagaki, Y., Yoshimitsu, Y., Hatip‐Al‐Khatib, I., Mishima, K., & Fujiwara, M. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.698 · Cited by 29
Okereke, O. I., Selkoe, D. J., Pollak, M., Stampfer, M. J., Hu, F. B., Hankinson, S. E., & Grodstein, F. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2089 · Cited by 25
Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease
Ballard, C. G., Corbett, A., & Sharp, S. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.13 · Cited by 21
Self-citationBranconnier, R. J., Branconnier, M. E., Walshe, T. M., McCarthy, C., & Morse, P. A. (1992) · PubMed · Cited by 19
Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin.
Eisenhardt, E. U., & Bickel, M. H. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08301-1 · Cited by 14
Landmark, K. H., Forsman, M., Lindberg, K. A., Ryman, T., Martmann-Moe, K., Haaverstad, S., & Wiel, S. (1995) · PubMed · Cited by 12
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3
Cited by
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
The vascular depression hypothesis: mechanisms linking vascular disease with depression
Taylor, W. D., Aizenstein, H. J., & Alexopoulos, G. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.20 · Cited by 923
Lysosomes as a therapeutic target
Bonam, S. R., Wang, F., & Muller, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0036-1 · Cited by 759
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Metadata
- Authors
- Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., Kearns, I., Kehoe, P., Mudher, A., Passmore, A., Shepherd, N., Walsh, F., & Ballard, C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-11
- Volume
- 11
- Issue
- 11
- Pages
- 833-846
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2084899590
- Cited by
- 301
- References
- 140
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.